Introduction
Despite wide use of antiretroviral therapy (ART), poor penetration of antiretroviral drugs across the blood-brain barrier (BBB) undermines the control of HIV-1 replication in brain macrophages, the primary targets of HIV-1 infection in the central nervous system (CNS) [1] . Mononuclear phagocytes (brain macrophages and microglia) serve as viral reservoirs in the brain and are potential sources of HIV-1 re-seeding after ART interruptions. Given inefficient penetration of antiretroviral drugs across the BBB and chronic neuroinflammation as a cause of HIV-1-associated dementia, the nuclear receptor, peroxisome proliferators-activated receptor gamma (PPARg) could be an attractive therapeutic target.
PPARg is expressed in many tissues and cell types, including monocytes, macrophages [2] [3] [4] [5] and is upregulated upon immune activation [6] . PPAR mediate transcriptional regulation of target genes by two mechanisms, transduction and transrepression. In the former, coactivators interact with nuclear receptors in a liganddependent manner affecting the gene transcription, whereas in the transrepression, gene transcription occurs via negative interference of PPAR with other signaltransduction pathways [3, 4] . After activation by specific agonists, these receptors form dimers and translocate to the nucleus, where they act as agonist-dependent transcription factors and regulate gene expression by binding to specific promoter regions of target genes (mechanism of upregulated genes). However, for negative regulation, ligand activation of PPARg antagonizes the activation of transcription factors [such as activator protein-1 (AP-1) and NF-kB], which results in suppression of gene expression [i.e. nitric oxide, tumor necrosis factor-a (TNFa) and interleukin-1b] [3, 4] . The potential therapeutic efficacy of PPARg ligands in neuroinflammatory and neurodegenerative diseases is highlighted by a large body of work in animal models for multiple sclerosis, Parkinson and Alzheimer diseases [7] [8] [9] [10] [11] [12] [13] [14] .
Although PPARg agonists were shown to inhibit HIV-1 replication in macrophages and T lymphocytes in vitro [15, 16] , the mechanisms of PPARg ligand effects remain elusive. The current study delineated the pathway by which PPARg ligands block HIV-1 replication and explored the idea that PPARg stimulation can efficiently block HIV-1 replication in vivo. Using a potent PPARg synthetic ligand, rosiglitazone, we showed significant reduction of HIV-1 replication in human monocytederived macrophages (MDM). We found that the decrease in virus replication was in response to the downmodulation of HIV-1 long terminal repeat (LTR) promoter activity by PPARg via inhibition of NF-kB. Finally, using a well developed animal model for HIV-1 encephalitis (HIVE) [17] , we demonstrate efficient suppression of HIV-1 replication in brain macrophages and lymphocytes in blood suggesting that PPARg activation can ameliorate HIV-1 CNS and systemic infection.
Materials and methods
Cell isolation and culture Monocytes and peripheral blood lymphocytes (PBL) were obtained by countercurrent centrifugal elutriation of leukopheresis packs from HIV-1, 2 and hepatitis B seronegative donors and monocytes were cultured as described [18] . 
Virus infection, PPAR-g ligand treatment and
HIV-1 p24 ELISA Monocytes or MDM (after 7 days in culture in presence of macrophage-colony stimulating factor) were pretreated with PPARg ligand (rosiglitazone, 50 mmol/l; Cayman Chemical, Ann Arbor, Michigan, USA), PPARg antagonist (GW9662, 50 mmol/l) or 3 0 -azido-2 0 , 3 0 -dideoxythymidine (ZDV, 10 mmol/l) and infected for 18 h with macrophage-tropic strain, HIV-1 ADA at multiplicity of infection of 0.1 [19] . MDM viability was evaluated by live/ dead cell assay (Invitrogen, Carlsbad, California, USA, data not shown), and HIV-1 p24 levels were measured by ELISA (Beckman Coulter, Miami, Florida, USA) according to the manufacturer's instructions.
DNA and short hairpin (sh)RNA against PPAR-g HIV-1 LTR and pCEP4 transactivation activator (Tat) expression plasmid constructs were obtained from AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National institutes of Health (NIH). shRNA were designed against human PPARg transcript (GenBank accession number NM138711) for knockdown of PPARg expression as described elsewhere [20] . Oligonucleotides coding for shRNA and scrambled were cloned into pRNAT-H1.1/Adeno vector and obtained from GenScript (Piscataway, New Jersey, USA). The shRNA constructs were bicistronic for green fluorescent protein (GFP) expression, allowing for assessment of transfection efficiency (data not shown).
Transfection and luciferase assay
Transient infections of HEK 293 cells was carried out using Lipofectamine 2000 (Invitrogen). Transfections of primary cells (monocytes or macrophages) were performed by Nucleofection according to the manufacturer's instruction (Amaxa Biosystem, Gaithersburg, Maryland, USA). In brief for each transfection, 9 Â 10 6 cells were resuspended in 100 ml of Nucloefector solution either with the PPARg response elements (PPRE, Panomics, Fremont, California, USA) linked to the luciferase reporter (1 mg), HIV-1 LTR luciferase reporter (1 mg) alone or together with PPARg or scrambled shRNA (1 mg). The instrument programs (Y-01 for monocytes and Y-10 for macrophages) were used and the transfection efficiency determined by fluorescent-activated cell sorting (FACS) was 85-89% and 50-60% for moncytes and macrophages, respectively (data not shown). The luciferase reporter assays were performed on a fluorescence plate reader with luminometer function (M5; Molecular Devices, Sunnyvale, California, USA) according to the manufacturer's protocol.
Western blotting
Protein lysates from human monocytes or macrophages ($9 Â 10 6 /per condition) 48 h posttransfection were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis. PPARg or a-actin was detected by western blotting using antibodies to PPARg (SC-7273; Santa Cruz Biotech, Santa Cruz, California, USA) at 1 : 1000 and a-actin (Chemicon, Temecula, California, USA) at 1 : 2000 dilutions, respectively.
PPAR-g and NF-kB binding assay
PPARg transcriptional activation and HIV-1 induced NF-kB p65 activation was determined using the TransAM kits (Active Motif, Carlsbad, California, USA). Nuclear extracts from macrophages or monocytes were prepared by using a nuclear extraction kit (Sigma, St Louis, Missouri, USA). For HIV-1 induced NF-kB p65 activation monocytes/macrophages were transfected (HIV-1 LTR luciferase reporter) and pretreated with rosgilitazone (50 mmol/l) and infected for 30 min (maximum activation of NF-kB p65 was observed at 30 min postinfection). The assays were performed according to the manufacturer's protocol and the transcriptional activation was quantified using a fluorescence plate reader (M5; Molecular Devices).
Generation of hu-PBL-NOD/SCID HIV-1 encephalitis mice and drug administration
Four-week-old male NOD/C.B-17 SCID mice purchased from Jackson Laboratory (Bar Harbor, Maine, USA) were maintained in sterile microisolator cages under pathogen-free conditions in accordance with ethical guidelines for care of laboratory animals at the University of Nebraska Medical Center (UNMC) and NIH. The hu-PBL-NOD/SCID (peripheral blood lymphocytes-NOD/SCID) HIVE mice were generated as described [17] . Rosiglitazone pills were purchased from the UNMC pharmacy, pulverized, mixed with carboxymethylcellose and almond paste, and administered orally (10 mg/kg/day). Drug treatment started 1 day prior to HIV-1 MDM intracerebral (i.c.) injection and continued for the entire duration of the experiment. Mice were sacrificed at 7, 14, and 21 d after i.c. injection with human MDM. In-vivo experiments were repeated twice.
Flow cytometric analysis
FACS was performed on mononuclear cells from blood and spleen at week 1-3 after i.c. injection of human MDM as described [18] . Data analysis was performed with a FACS Calibur using CellQuest software (Becton Dickinson Immunocytometry System, San Jose, California, USA). Fluorochrome-conjugated monoclonal antibodies (mAb) to human CD4, CD8, and CD3 were used and fluorescein isothiocyanate conjugated antimouse CD45 mAb were included to exclude murine cells. Control and rosiglitazone-treated MDM were labeled with anti-CXCR4 and anti-CCR5 fluorescent conjugates and sorted on a flow cytometer. Alexa Flour conjugated anti-PPARg antibody (Santa Cruz Biotech) was used to detect PPARg expression on CD14-positive gated macrophages. Unless otherwise mentioned, all antibodies were obtained from eBioscience (San Diego, California, USA).
Histopathology and image analysis
Mice were sacrificed at 7, 14, and 21 d after i.c. injection of human MDM, tissues were fixed in 4% phosphatebuffered paraformaldehyde and paraffin embedded. Immunohistochemistry, histopathologic evaluation and image analyses were carried out as described [17] . Primary antibodies were purchased from Dako Carpentaria, California, USA (CD68, CD8, vimentin and HIV-1 p24). The numbers of CD8, CD68 MDM, and HIV-1 p24 cells in each section were counted in a blinded fashion by three independent observers.
Statistical analysis
Results were presented as mean AE SD, and P values less than 0.05 were considered significant. Data were analyzed using Prism (Graph Pad; GraphPad Software, Inc., La Jolla, California, USA) and statistical significance for multiple comparisons was assessed by one-way analysis of variance with Newman-Keuls posttest. All in vitro assays were repeated at least twice (each condition in triplicate).
Results

Rosiglitazone inhibits HIV-1 replication in human MDM
PPARg activation by ligands such as thiazolidinediones (TZD) has been shown to play a role in cellular proliferation, differentiation, inflammation [21, 22] , and inhibition of HIV-1 replication [15] . Rosiglitazone (50 mmol/l) treated macrophages produced lower levels of HIV-1 p24 after infection (P < 0.05, Fig. 1a ). Rosiglitazone (50 mmol/l) activated PPARg as indicated by stimulation of PPARg transcriptional activity ( Fig. 1b) . Given the complex biological effects of PPARg ligand [23] and decreased PPARg expression in HIV-1-infected patients [24] , we tested whether rosiglitazone had any affect on HIV-1 coreceptor expression and whether HIV-1 infection modulated PPARg protein expression in macrophages. Expression levels of CXCR4/CCR5 receptors ( Fig. 1c ) and PPARg protein levels (Fig. 1d ) were not downregulated in macrophages treated with rosiglitazone or infected with HIV-1. Similar experiments using luciferase reporter assay for PPRE further established that infection alone had no effect on PPARg activity whereas macrophage treatment with rosiglitazone (50 mmol/l) induced a 7.5-fold increase in PPARg reporter activity ( Fig. 1e ). Taken together, these data sug-gest that rosigiltazone induced PPARg activation and that this stimulation may be involved in inhibition of HIV-1 infection in macrophages.
PPAR-g activation suppresses HIV-1 LTR promoter activity
Expression of HIV-1 provirus is regulated by interaction of cellular and viral transcription factors that bind to HIV-1 LTR [25] [26] [27] . Therefore, we explored whether activation of PPARg could suppress HIV-1 LTR activity. To test this idea, TZM-bl cells were infected with HIV-1 ADA , and 48 h postinfection luciferase levels (indicating HIV-1 LTR activity) were determined. Rosiglitazone treatment (0-100 mmol/l) resulted in a dose-dependent suppression of HIV-1 LTR activity and PPARg antagonist (GW9662, 50 mmol/l) abolished the effects of rosiglitazone ( Fig. 2a) . As Tat is a powerful viral transactivator and plays a central role in viral replication, we tested whether activation of PPARg could suppress HIV-1 LTR activity. Rosiglitazone at various concentrations (0-100 mmol/l) did not significantly affect induction of HIV-1 LTR by Tat. However, Tat-independent transactivation of the HIV-1 LTR by TNFa (100 ng/ml) was suppressed (Fig. 2b) . As transcriptional activation of the HIV LTR by TNFa is associated with the induction of a nuclear factor(s) binding to the NF-kB sites of the LTR, it is likely that the PPARg-mediated LTR suppression is mediated by cellular factors rather than viral elements.
Monocytes are the cells that presumably carry HIV-1 to the brain [28] where they establish viral reservoirs that differentiate into macrophages. Therefore, we investigated the effects of PPARg stimulation in primary human monocytes. Infection of monocytes transfected with HIV-1 LTR luciferase induced a 15-fold increase in LTR activity, and rosiglitazone treatment resulted in its fivefold inhibition (Fig. 2c ). Collectively, these results suggested that PPARg stimulation led to suppression of HIV-1 LTR activation.
PPAR-g silencing impairs the effects of rosiglitazone on HIV-1 suppression and binding of NF-kB to HIV-1 LTR
To investigate the specificity of rosiglitazone effects on HIV-1 LTR activation, we sought to knockdown expression of PPARg by shRNA. Multiple shRNA constructs targeting PPARg nuclear receptors were designed and the sequence (shPPARg-2) that provided most optimal knockdown of endogenous level of PPARg in primary human monocytes ( Fig. 3a) and macrophages ( Fig. 3b ) was selected. HIV-1 LTR activation was efficiently suppressed by rosiglitazone in HIV-1 infected cells and also in those that were transfected with the scramble shRNA (control). In contrast, expression of PPARg shRNA in cells infected and treated with rosiglitazone resulted in lack of HIV-1 LTR suppression both in monocytes ( Fig. 3c ) and macrophages (Fig. 3d) . These results indicated that the rosiglitazone mediated effects were PPARg specific and rule out the possible involvement of other PPAR subtypes in mediating the effect of rosiglitazone on HIV-1 suppression.
Because transrepression or negative interaction with NF-kB are suspected to underlie the effects of PPARg stimulation [29] [30] [31] [32] [33] [34] [35] [36] and NF-kB is one of the central transcription factors that bind the HIV-1 LTR, we investigated the effect of rosiglitazone on the DNAbinding activity of NF-kB. Rosiglitazone treatment of monocytes ( Fig. 3e ) or macrophages (Fig. 3f ) diminished HIV-1 induced NF-kB DNA-binding activity as compared with control (P < 0.05). Transfection of shRNA vectors, to knock down endogenous PPARg expression abolished the effect of rosiglitazone on the DNA-binding activity while irrelevant shRNA had no effect. Together, these results suggest that the PPARg ligand could suppress HIV-1 replication via modulation of binding of NF-kB to the HIV-1 LTR promoter.
Rosiglitazone suppressed viremia in an animal model for HIV-1 infection
To determine whether PPARg ligand can suppress HIV-1 replication in vivo, we investigated the effect of rosiglitazone in our mouse model for HIVE [17, 18] . NOD/SCID mice were reconstituted with human PBL (hu-PBL-NOD/ SCID) and inoculated i.c. with autologous HIV-1 infected MDM. Animals (n ¼ 5-8 mice/group/week) were orally fed daily with rosiglitazone (10 mg/kg) or placebo and sacrificed at weeks 1, 2, and 3 after MDM inoculation. Similar percentages of CD4, CD8, and CD3 cells observed between the two groups (data not shown) assessed by flow cytometry analysis on cells derived from blood and spleen of hu-PBL-NOD/SCID HIVE mice assured comparability of the results between groups. Viremia was measured by ELISA (HIV-1 p24) and expressed in pg/ml per 1000 CD4 cells. Two weeks following the i.c. injection of HIV-1 infected MDM, both rosiglitazone and control animals (33.7 AE 9. 5 vs. 37.3 AE 15.7) had equally low levels of HIV-1 p24. At week 3, when infection spread from HIV-1-infected MDM to circulating CD4 lymphocytes control animals demonstrated high levels of viremia while rosiglitazone treated mice had a 50% reduction in HIV-1 p24 levels (P < 0.02, Fig. 4a ).
Rosiglitazone suppressed HIV-1 replication in brain macrophages in hu-PBL-NOD/SCID HIV-1 encephalitis mice
To examine whether rosiglitazone treatment can affect HIV-1 replication in brain macrophages, serial brain sections were immunostained for human CD68 (a marker for human MDM), HIV-1 p24 (viral antigen), and human CD8 (T lymphocytes indicating an antiviral responses). A prominent reduction of HIV-1 p24 MDM was noted in rosiglitazone treated mice (Fig. 4c ) at week 1 as compared with controls ( Fig. 4b) . Similarly, at week 2 rosiglitazone treated mice (Fig. 4e ) featured fewer HIV-1 p24 MDM (Fig. 4d ). The level of virus replication, elimination of virus-infected macrophages and CD8 cell infiltration were quantitatively analyzed by counting CD68, HIV-1 p24, and CD8 lymphocytes in brain tissue sections in a blinded fashion by three independent observers. As shown in (Fig. 5a ), the mean numbers of CD68 MDM in the rosiglitazone and control groups were similar at weeks 1-3. The percentage of infected macrophages was significantly lower in rosiglitazone as compared with controls at week 1 and 2 (P < 0.05, Fig. 5b) , and a similar trend was found at week 3. At week 1, fewer HIV-1 p24 MDM were found in rosiglitazone mice as compared with controls (130 AE 34.8 vs. 47.2 AE 21.5, P< 0.05, . 5c ). A similar trend existed at week 2; however, differences failed to reach statistical significance (47.9 AE 17.2 vs. 22 AE 7.8, P > 0.05). Comparable amounts of CD8 T cells were detected at weeks 1 and 2 in rosiglitazone and control mice (Fig. 5d ). These finding suggest that oral administration of rosiglitazone was effective in diminishing viral replication in brain macrophages and blood CD4 lymphocytes of hu-PBL-NOD/ SCID HIVE mice.
Discussion
Several lines of evidence indicate that PPARg natural and synthetic ligands such as TZDs control brain inflammation by inhibiting microglial activation, and synthesis of nitric oxide, prostaglandins, chemokines, and inflammatory cytokines [12, 14, 37, 38] . CNS inflammation during HIV-1 infection is driven in part by HIV-1 replication, which utilizes cellular transcription factors. Hence, we sought to evaluate whether PPARg, via inhibition of transcription factors important in proinflammatory responses, could attenuate HIV-1 replication. PPARg ligand treatment resulted in a significant decrease of virus infection in primary human MDM, the major virus reservoir in the brain. TZD are rapidly absorbed by oral administration and efficiently permeate the BBB [39] . Capitalizing on this ability of TZD, we evaluated the effect of PPARg activation on HIV-1 infection in a mouse model of HIVE. Animals fed with PPARg ligand, rosiglitazone showed a 50% reduction of viremia and diminished HIV-1 replication in human MDM inoculated into mice brains.
PPARg, a member of the family of nuclear factors is expressed in abundance in macrophages and lymphocytes [4, 40] . In addition to upregulation of target genes, PPARg also forms repressor complexes (transrepression) to downregulate genes induced by other transcription factors (reviewed in [41, 42] ). It is through transrepression that PPARg ligands act as anti-inflammatory agents by inhibition of AP-1, NF-kB, and STAT-1 either by direct interaction or sequestration of essential cofactors [4, 36, 43, 44] . Although previously Hayes et al. [15] speculated that transcriptional and posttranscriptional effects could be responsible for inhibited virus replication in macrophages by PPARg ligands, the mechanism of virus suppression remained elusive. Our study found that activation of PPARg receptor with the ligand rosiglitazone suppressed HIV-1 LTR activity both in a HIV-1 LTR stable transfected cell line and in primary mononuclear cells. Moreover, the replication of HIV-1 was inhibited by rosiglitazone in human macrophages. We also showed that the effect of the ligand was specific to PPARg, as rosiglitazone failed to attenuate the induction of HIV-1 LTR promoter activity (HIV-1 infection) in monocytes expressing PPARg specific shRNA or in the presence of antagonist.
The role of NF-kB in activation of HIV-1 transcription was analyzed [45] which is of particular importance as it is stimulated by several cytokines involved in immune and inflammatory responses [25] . NF-kB is one of the several transcription factors that strongly induces HIV-1 LTR. PPARg activation in HIV-1 infected monocytes reduced the NF-kB-DNA binding activity similar to findings in other studies where PPARg stimulation downregulated NF-kB-DNA binding in a variety of cell types [46, 47] . Consequently, ligand treatment had no effect on NF-kB binding in infected monocytes with diminished PPARg receptor expression. There is a possibility that PPARg could inhibit LTR activity by interfering with HIV-1 protein, Tat. Tat is a key regulatory protein of HIV-1 and its ability to stimulate HIV transcription from the LTR [48] via RNA rather than DNA promoter elements is unique among transcriptional activators. Although HIV-1 LTR contains binding sites for multiple cellular transcription factors, it is primarily targeted by HIV-1 Tat. Interestingly, PPARg had no effect on HIV-1 Tatmediated induction of the LTR, which explains the partial inhibition of HIV-1 replication (via NF-kB inhibition). These findings indicated that suppression of HIV-1 replication in monocytes/macrophages is achieved via suppression of NF-kB activation.
Our results suggested that PPARg ligand activation in HIV-1 infected monocytes downregulated NF-kB DNA activity through a transrepression that involves p65 subunit of NF-kB and PPARg resulting in decreased HIV-1 LTR transcription and HIV-1 virus replication. Nevertheless, the possibility of PPARg ligand-mediated suppression of HIV-1 virus independent of NF-kB transrepression cannot be completely ruled out. For instance, PPAR ligands can activate kinases that lead to phosphorylation cascades that, in turn, trigger transcriptional changes leading to several levels of downstream regulation (reviewed by Diradourian et al. [49] and Gardner et al. [50] ). They also can alter ligand binding, corepressor/coactivator recruitment, or heterodimerization with retinoid X receptor a, all of which influencing PPAR-mediated transcription (reviewed in Peraza et al. [51] ). Whether these interactions play any role in suppression of HIV-1 still remains to be elucidated. Beneficial effects of PPARg stimulation were demonstrated in a variety of animal models of inflammatory and neurodegenerative disorders (reviewed by Moraes et al. [52] , Bernardo and Minghetti [37] ). Our in vivo model of HIVE recapitulates adaptive and innate immune responses, immunopathological features of HIV-1 CNS infection (including neuroinflammation and neuronal demise), and viremia, [17, 53] . These features are relevant for the chronic immune activation seen in HIV-1 infection driven by activation of NF-kB and increased viral transcription [54] [55] [56] .
In vivo results supported the in vitro observations showing that PPARg receptor stimulation reduced viremia and suppressed HIV-1 infection in MDM in the brain. As CNS macrophages are a major viral reservoir poorly accessible by ART [57] , these findings are of particular interest since effects of PPARg ligand on HIV-1 replication might not be prevailed by viral mutations. The dose of rosiglitazone used in our animal studies did not affect PBL engraftment levels and was within the range used for patient treatment. Antigenspecific CD8 T lymphocytes serve a prominent role in the control of HIV-1 infection of brain macrophages in the hu-PBL-NOD/SCID mouse model of HIVE [17, 18] . PPARg treatment did not affect the number of brain infiltrating CD8 T lymphocytes. Whether PPARg stimulation provides additional immunomodulatory or anti-inflammatory effects awaits future investigation.
In summary, our results suggest that the suppressive mechanism of PPARg ligand involves transrepression of NF-kB and decreased HIV-1 LTR promoter transcription. In-vitro and in-vivo data strongly support potential use of PPARg for treatment of HIVE and suppression of HIV-1 replication in lymphocytes and MDM thus offering new therapeutic intervention in brain and systemic infection.
